GSK mRNA flu shot to enter phase III in 2026
Rhea-AI Filing Summary
GSK plc (GSK) reported positive phase II results for its investigational mRNA seasonal influenza vaccine and plans to advance the optimised candidate FLUm3HA.b-3NA into a phase III efficacy trial starting in September 2026. In a 971‑adult phase II trial, the vaccine generated higher immune responses against all tested influenza strains than licensed standard‑dose and high‑dose inactivated flu vaccines in younger and older adults, and was generally well tolerated.
The vaccine is designed to target both haemagglutinin (HA) and neuraminidase (NA), the two primary influenza surface antigens, whereas licensed vaccines primarily target HA. The programme is part of GSK’s broader respiratory vaccines research, and the candidate has received US FDA Fast Track designation for the targeted age indication.
Positive
- mRNA flu candidate moves to phase III with Fast Track status: GSK will advance its HA/NA‑targeting mRNA seasonal flu vaccine into a phase III efficacy trial in September 2026 after positive phase II immunogenicity and safety data, and the US FDA has granted Fast Track designation for the targeted age indication.
Negative
- None.
Filing Explained
Although GSK intends to start the FLUm3HA.b-3NA phase III efficacy trial in September 2026, the September 1 6-K states that the investigational mRNA vaccine is not approved anywhere, so the disclosure marks planned next-stage testing—not an approved product or completed phase III efficacy result.
Key Figures
Phase II trial participants: 971 adults
Adult age groups in trial: 18-64 and ≥65 years
Phase III trial timing: September 2026
+4 more
7 metrics
Phase II trial participants
971 adults
Adults 18 years of age and older in the Flu-028 phase II mRNA flu vaccine trial
Adult age groups in trial
18-64 and ≥65 years
Age cohorts receiving different dose levels in the Flu-028 phase II trial
Phase III trial timing
September 2026
Planned start date for the phase III efficacy trial of FLUm3HA.b-3NA
Fast Track designation date
July 2026
Month and year when the US FDA granted Fast Track designation
Global seasonal influenza cases
around one billion cases per year
Worldwide annual burden of seasonal influenza cited from WHO
Severe seasonal influenza cases
up to 5 million cases per year
Global annual severe illness cases from seasonal influenza
Seasonal influenza respiratory deaths
up to 650,000 per year
Global annual respiratory deaths attributed to seasonal influenza
Key Terms
Fast Track designation, haemagglutinin (HA), neuraminidase (NA), immunogenicity, +2 more
6 terms
Fast Track designation regulatory
"In July 2026, the US Food and Drug Administration (FDA) granted the vaccine candidate Fast Track designation"
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.
haemagglutinin (HA) medical
"designed to target both haemagglutinin (HA) and neuraminidase (NA), the primary surface antigens"
neuraminidase (NA) medical
"designed to target both haemagglutinin (HA) and neuraminidase (NA), the primary surface antigens"
immunogenicity medical
"Flu-028 is a randomised, observer-blind phase II trial assessing the immunogenicity and safety"
Immunogenicity is the ability of a substance, such as a vaccine or medication, to provoke an immune response in the body. It matters to investors because high immunogenicity can affect the effectiveness and safety of a product, potentially leading to increased costs or regulatory challenges. Understanding immunogenicity helps assess the long-term viability and market potential of pharmaceutical and biotech investments.
reactogenicity medical
"Immunogenicity and reactogenicity/safety data up to day 181 post-vaccination were assessed"
Reactogenicity is the tendency of a drug or vaccine to produce short-term, physical reactions—like soreness at the injection site, fever, or fatigue—that reflect the body’s immediate response to the product. Investors care because higher or unexpected reactogenicity can influence regulatory reviews, public acceptance, prescription and vaccination rates, and therefore sales forecasts and company valuation, much like how customer reviews shape demand for a consumer product.
observer-blind technical
"Flu-028 is a randomised, observer-blind phase II trial assessing the immunogenicity"
Observer-blind describes a study setup where the people who evaluate results do not know which treatment each participant received, even if others involved might know. For investors, this matters because it reduces the chance that personal expectations or knowledge will skew measurements of effectiveness or safety, making reported outcomes more reliable—similar to a referee judging a game without knowing which team used a new piece of equipment.
FAQ
What did GSK (GSK) announce about its mRNA seasonal flu vaccine?
GSK announced positive phase II data for its mRNA seasonal influenza vaccine candidate, showing higher immune responses versus licensed standard‑dose and high‑dose inactivated flu vaccines, and stated it intends to start a phase III efficacy trial in September 2026 with the optimised FLUm3HA.b-3NA candidate.
How many participants were in GSK’s phase II flu vaccine trial (GSK)?
The Flu‑028 phase II trial enrolled 971 adults 18 years of age and older. Adults aged 18–64 and ≥65 years received different dose levels of the mRNA vaccine candidates or age‑appropriate licensed comparators, with immunogenicity and safety assessed up to day 181 post‑vaccination.
What makes GSK’s mRNA flu vaccine candidate different from current vaccines?
GSK’s investigational mRNA seasonal flu vaccine is designed to target both haemagglutinin (HA) and neuraminidase (NA), the primary surface antigens of influenza. Licensed flu vaccines primarily target HA, and GSK notes growing evidence that including NA may improve protection, illness severity and transmission.
When will GSK (GSK) start the phase III trial of its mRNA flu vaccine?
GSK states it intends to start a phase III efficacy trial in September 2026 using the optimised B‑strain HA candidate FLUm3HA.b-3NA, following robust HA and NA immune responses and acceptable safety and reactogenicity observed in the Flu‑028 phase II trial.
Has GSK’s mRNA seasonal flu vaccine been approved anywhere?
No. GSK explicitly states that its investigational mRNA seasonal flu vaccine candidate is not approved anywhere in the world. It remains in clinical development, moving from phase II to a planned phase III efficacy trial after the reported positive phase II results.
What regulatory status has GSK’s mRNA flu vaccine candidate received?
In July 2026, the US Food and Drug Administration granted the vaccine candidate Fast Track designation for the targeted age indication, which GSK describes as reflecting the urgent need to improve flu protection with new seasonal influenza vaccination approaches.
How significant is seasonal flu according to GSK’s 6-K disclosure for GSK?
GSK cites World Health Organization data that seasonal influenza causes around one billion cases globally each year, including up to 5 million cases of severe illness and up to 650,000 respiratory deaths, underscoring the substantial global health burden and need for improved vaccines.
AI-generated analysis. How Rhea-AI works. Not financial advice.
